WhatsApp Group Join Now

Replimune Announces Priority Review for Melanoma Treatment (NASDAQ:REPL)

  • RepliMoney Group (Nasdaq: Reply) announced that the US Food and Drug Administration has accepted a biosimilar license application for RP1 in combination with nivolumab for patients with advanced melanoma.
  • The FDA granted BLA priority review to the prescription drug user

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top